HN30
Restart Life Sciences Corp., through its subsidiaries, operates as a biotechnology company worldwide. It engages in developing natural remedies specifically tailored for individuals on the autism spectrum; health-related foods that promote both mind and body wellness for healthy living, as well as psilocybin clinical trial for fragile X syndrome. The company was formerly known as Nova Mentis Life… Read more
HN30 (HN30) - Total Liabilities
Latest total liabilities as of September 2025: €301.63K EUR
Based on the latest financial reports, HN30 (HN30) has total liabilities worth €301.63K EUR as of September 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
HN30 - Total Liabilities Trend (2021–2024)
This chart illustrates how HN30's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
HN30 Competitors by Total Liabilities
The table below lists competitors of HN30 ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Cortus Energy AB (publ)
ST:CE
|
Sweden | Skr83.05 Million |
|
REPUBLIC SERVICES (RPU.SG)
STU:RPU
|
Germany | €20.58 Billion |
|
Current Water Technologies Inc
PINK:ENPRF
|
USA | $1.66 Million |
|
Marvel Discovery Corp
OTCQB:MARVF
|
USA | $1.56 Million |
|
HERSHEY - Dusseldorf Stock Exchang
DU:HSY
|
Germany | €8.42 Billion |
Liability Composition Analysis (2021–2024)
This chart breaks down HN30's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 0.48 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | -2.03 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 1.97 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how HN30's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for HN30 (2021–2024)
The table below shows the annual total liabilities of HN30 from 2021 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | €489.47K | -41.85% |
| 2023-12-31 | €841.66K | +229.49% |
| 2022-12-31 | €255.44K | -39.48% |
| 2021-12-31 | €422.06K | -- |